Following validation, we applied the PTV-IIIab-based taRNA to activate protein production from haploinsufficiency-disease-relevant genes, including SYNGAP1, whose haploinsufficiency causes developmental delay, epilepsy, and autism4; and PMP22, whose haploinsufficiency results in Hereditary Neuropathy with Liability to Pressure Palsies (HNPP)51. The gene discussed is PMP22; the disease is epilepsy.